These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 15527403)

  • 1. Pharmaceuticals and the consumer movement: the ambivalences of 'patient power'.
    Lofgren H
    Aust Health Rev; 2004 Nov; 28(2):228-37. PubMed ID: 15527403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of patient advocacy organisations in neuromuscular disease R&D--The case of the Dutch neuromuscular disease association VSN.
    Boon W; Broekgaarden R
    Neuromuscul Disord; 2010 Feb; 20(2):148-51. PubMed ID: 20106662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Making a difference: why perianesthesia nurses must be involved in the policy and political process.
    Leavitt JK
    J Perianesth Nurs; 2008 Jun; 23(3):157-62. PubMed ID: 18501835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No exit and the organization of voice in biotechnology and pharmaceuticals.
    Light DW; Castellblanch R; Arredondo P; Socolar D
    J Health Polit Policy Law; 2003; 28(2-3):473-507. PubMed ID: 12836894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [European drug policy: welcomed modernization but shortage of political proposals concerning industry and research].
    Alván G
    Lakartidningen; 2003 Oct; 100(44):3541-2. PubMed ID: 14651017
    [No Abstract]   [Full Text] [Related]  

  • 6. Challenges to pharmaceutical policymaking: lessons from Australia's national medicines policy.
    Lipworth W; Doran E; Kerridge I; Day R
    Aust Health Rev; 2014 May; 38(2):160-8. PubMed ID: 24589424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmaceutical policy in Italy: Theory, politics and practice.
    Garattini L; Cornago D
    Eur J Health Econ; 2006 Jun; 7(2):89-90. PubMed ID: 16688431
    [No Abstract]   [Full Text] [Related]  

  • 8. Generating political priority for regulatory interventions targeting obesity prevention: an Australian case study.
    Baker P; Gill T; Friel S; Carey G; Kay A
    Soc Sci Med; 2017 Mar; 177():141-149. PubMed ID: 28161671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Globalization, pharmaceutical pricing, and South African health policy: managing confrontation with U.S. firms and politicians.
    Bond P
    Int J Health Serv; 1999; 29(4):765-92. PubMed ID: 10615573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global Health Warning: Definitions Wield Power Comment on "Navigating Between Stealth Advocacy and Unconscious Dogmatism: The Challenge of Researching the Norms, Politics and Power of Global Health".
    Marten R
    Int J Health Policy Manag; 2015 Dec; 5(3):207-9. PubMed ID: 26927595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient Advocacy Organizations, Industry Funding, and Conflicts of Interest.
    Rose SL; Highland J; Karafa MT; Joffe S
    JAMA Intern Med; 2017 Mar; 177(3):344-350. PubMed ID: 28114624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addressing the theoretical, practical and ethical challenges inherent in prospective health policy analysis.
    Buse K
    Health Policy Plan; 2008 Sep; 23(5):351-60. PubMed ID: 18664524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Better pharmaceutical price comparison studies are needed for meaningful evaluation of price-control policies.
    Value Health; 2008; 11(1):129-30. PubMed ID: 18179656
    [No Abstract]   [Full Text] [Related]  

  • 14. Advocacy group sees little progress toward an HIV vaccine.
    AIDS Policy Law; 1998 May; 13(10):1, 8-9. PubMed ID: 11365444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The subsidy of pharmaceuticals in Australia: processes and challenges.
    Sansom L
    Aust Health Rev; 2004 Nov; 28(2):194-205. PubMed ID: 15527399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New NICE criteria for drug access.
    Fricker J
    Lancet Oncol; 2017 May; 18(5):576. PubMed ID: 28343973
    [No Abstract]   [Full Text] [Related]  

  • 17. New federal guidelines for physician-pharmaceutical industry relations: the politics of policy formation.
    Chimonas S; Rothman DJ
    Health Aff (Millwood); 2005; 24(4):949-60. PubMed ID: 16136634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physicians and the state in the U.S.A. and Israel.
    Yishai Y
    Soc Sci Med; 1992 Jan; 34(2):129-39. PubMed ID: 1738866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease Campaigns and the Decline of Treatment Advocacy.
    Best RK
    J Health Polit Policy Law; 2017 Jun; 42(3):425-457. PubMed ID: 28213392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cultural understanding of research ethics governance.
    Brunger F; Burgess M
    Health Law Rev; 2005; 13(2-3):69-74. PubMed ID: 16459417
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.